Key facts
- GlycanAge’s last known valuation is $17.0M (Jan 2024).
- It has raised $15.5M; the latest was Later Stage VC ($8.7M) in Aug 2025.
- Notable investors include Pareto Holdings, European Union, Hub71, Exceptional Ventures, Vesna Deep Tech Fund — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for GlycanAge
- ·The full record, as it builds
Funding rounds
No funding rounds for GlycanAge are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GlycanAge
Developer of a biological age test designed to discover, measure, and optimize longevity. The company collects a few drops of blood with a quick finger-prick test with analysis, viewing results in a personal online dashboard, and consulting with care throughout the process, enabling patients to know food intolerances and their true age.
- Sector
- Healthcare
- HQ
- Newcastle Upon Tyne, United Kingdom
- Founded
- 2016
- Employees
- 42
- Website
- glycanage.com/
- Ownership
- Privately Held (backing)
GlycanAge doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GlycanAge shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GlycanAge in its N-PORT filings yet. We sweep new filings monthly.